Abstract
The title of this review “War and peace” is not accidental and the analogies with a well-known literary masterpiece have absolutely justified ground. As in the case of Lev Tolstoy’s novel this title has a profound philosophical meaning, although at first glance it may seem quite obvious. The word «war» may well correspond to those hostile changes of microorganisms leading to the current problem of antimicrobial resistance recognized worldwide. This is the “war” we have to wage against the antibiotic-resistant bacteria today. And the «peace» in this context is considered as the world, the entire universe, all people, the whole society and its reaction to what is happening. On the other hand, the word «peace» means something opposite in meaning to the word «war». Thus, the essence of the title bears a sharp contrast between military actions and peacetime, between something that carries a threat to life and peace, or illness and recovery. Preserving original novel’s structure the authors of this review consistently consider justification of fosfomycin trometamol as a first-line drug in the treatment of acute uncomplicated cystitis in women taking into account the latest research, publications and global trends.
Smolensk State Medical University, Smolensk, Russia
Institute of Antimicrobial Chemotherapy, Smolensk, Russia
Institute of Urology and Interventional Radiology named after N.A. Lopatkin, Moscow, Russia
A.I. Yevdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia
Institute of Antimicrobial Chemotherapy, Smolensk, Russia
-
1.
EAU Guidelines. Edition presented at the EAU Congress Amsterdam the Netherlands, 2020. ISBN 978-94-9267107-3.
-
2.
Gupta K., Hooton T., Naber K., Wullt B., Colgan R., Miller L.G., et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52(5):e103-20.
DOI: 10.1093/cid/ciq257
-
3.
Perepanova T.S., Kozlov R.S., Rudnov V.A., Sinyakova L.A., Palagin I.S. Antimicrobial therapy and prophylaxis of infection of kidneys, urinary tract and male genital organs. Federal clinical guidelines. M.: Uromedia, 2020. 110 p. Russian.
-
4.
Oteo J., Pérez-Vázquez M., Campos J. Extendedspectrum beta-lactamase producing Escherichia coli: changing epidemiology and clinical impact. Curr Opin Infect Dis. 2010;23(4):320-326.
DOI: 10.1097/qco.0b013e3283398dc1
-
5.
Critchley I.A., Cotroneo N., Pucci M.J., Mendes R. The burden of antimicrobial resistance among urinary tract isolates of Escherichia coli in the United States in 2017. PLoS One. 2019;14(12):e0220265.
DOI: 10.1371/journal.pone.0220265
-
6.
Ny S., Kozlov R., Dumpis U., Edquist P., GrondahlYli-Hannuksela K., Kling A-M., et. al., NoDARS ESBLcarrier Working Group. Large variation in ESBL-producing Escherichia coli carriers in six European countries including Russia. Eur J Clin Microbiol Infect Dis. 2018;37(12):23472354.
DOI: 10.1007/s10096-018-3382-8
-
7.
Johansen T.E.B., Livermore D.M., Cai T., Tutone M. SURF (SUsceptibility and Resistance of uropathogens to Fosfomycin in comparison with other antimicrobial agents): an international microbiological surveillance study. Poster presented at the 40th Congress of the Societe Internationale d’Urologie, October 10-11, 2020, virtual.
-
8.
Cai T., Johansen T.E.B., Livermore D.M., Tutone M. Clinical implications of SURF-data (SUsceptibility and Resistance of uropathogens to Fosfomycin in comparison with other antimicrobial agents) on empirical treatment of uncomplicated urinary tract infections in women. Poster presented at the 40th Congress of the Societe Internationale d’Urologie, October 10-11, 2020, virtual.
-
9.
The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 11.0, 2021. Available at: www.eucast.org. Accessed March, 2021.
-
10.
CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 30th ed. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2020. Available at: www.clsi.org. Accessed March, 2021.
-
11.
Zhanel G.G., Walkty A.J., Karlowsky J.A. Fosfomycin: a first-line oral therapy for acute uncomplicated cystitis. Can J Infect Dis Med Microbiol. 2016;2016:2082693.
DOI: 10.1155/2016/2082693
-
12.
Palagin I.S., Sukhorukova M.V., Dekhnich A.V., Edelstein M.V., Perepanova T.S., Kozlov R.S., and DARMIS-2018 Study Group. Antibiotic resistance of pathogens causing community-aquired urinary tract infections in Russia: results of the multicenter study “DARMIS-2018”. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2019;21(2):134-146. Russian.
DOI: 10.36488/cmac.2019.2.134-146
-
13.
Patel S.S., Balfour J.A., Bryson H.M. Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. Drugs. 1997;53(4):637-656.
DOI: 10.2165/00003495-199753040-00007
-
14.
Bergan T., Mastropaolo G., Di Mario F., Naccarato R. In: Neu H., Williams J.D., editors. New trends in urinary tract infections. Basel Karger, 1988. P. 157-166.
DOI: 10.1159/isbn.978-3-318-04985-5
-
15.
Segre G., Bianchi E., Cataldi A., Zannini G. Pharmacokinetic profile of fosfomycin trometamol (Monuril). Eur Urol. 1987;13(Suppl 1):56-63.
DOI: 10.1159/000472864
-
16.
Kuiper S.G., Dijkmans A.C., Wilms E.B., Kamerling I.M.C., Burggraaf J., Stevens J., van Nieuwkoop C. Pharmacokinetics of fosfomycin in patients with prophylactic treatment for recurrent Escherichia coli urinary tract infection. J Antimicrob Chemother. 2020;75(11):3278-3285.
DOI: 10.1093/jac/dkaa294
-
17.
European Medicines Agency. Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics. Press release. November 16, 2018 EMA/795349/2018. Available at: www.ema.europa.eu/en/news/disabling-potentiallypermanent-side-effects-lead-suspension-restrictionsquinolone-fluoroquinolone. Accessed March, 2021.
-
18.
Bonkat G., Wagenlehner F. In the line of fire: should urologists stop prescribing fluoroquinolones as default? Eur Urol. 2019;75(2):205-207.
DOI: 10.1016/j.eururo.2018.10.057
-
19.
Cai T., Tamanini I., Tascini C., Köves B., Bonkat G., Gacci M., et al. Fosfomycin trometamol versus comparator antibiotics for the treatment of acute uncomplicated urinary tract infections in women: a systematic review and metaanalysis. J Urol. 2020;203(3):570-578.
DOI: 10.1097/JU.0000000000000620
-
20.
Philipps W., Fietz A.K., Meixner K., Bluhmki T., Meister R., Schaefer C., et al. Pregnancy outcome after first-trimester exposure to fosfomycin for the treatment of urinary tract infection: an observational cohort study. Infection. 2020;48(1):57-64.
DOI: 10.1007/s15010-01901342-1
-
21.
Araujo M., Benevent J., Sicard D., Damase-Michel C. Teratogenic risk of fosfomycin during the first trimester of pregnancy: a study with two complementary approaches within the EFEMERIS database. 47th Conference of the European Teratology Society (ETS), September 7-20, 2019, Cologne, Germany. Reprod Toxicol. 2019;88:137-138.
DOI: 10.1016/j.reprotox.2019.05.024
-
22.
Araujo M., Sicard D., Hurault-Delarue C., Montastruc J.L., Lacroix I., Damase-Michel C., et al. Exposure to fosfomycin trometamol during pregnancy: a descriptive study using the EFEMERIS database. the Annual Meeting of French Society of Pharmacology and Therapeutics, and INSERM Clinical Research Centers (CIC) Meeting, June 12-14, 2019, Lyon, France. Fundam Clin Pharmacol. 2019;33(Suppl. S1):27.
DOI: 10.1111/fcp.12469